Prophylactic application of modified vacuum-assisted closure therapy in Ivor Lewis esophagectomy: Preliminary results

Table 1 Patient demographics and baseline characteristics, n (%)

	Total (n = 31)	ModVAC (n = 16)	No-ModVAC (n = 15)	P value
Sex
Male	19 (64.5)	10 (62.5)	10 (66.7)
Female	11 (35.5)	6 (37.5)	5 (33.3)	0.801
Age (mean)	59	61	57	0.332
Comorbidities
DM	7 (23.3)	5 (33.3)	2 (13.3)	0.191
CAD	7 (23.3)	3 (20)	4 (26.7)	0.661
Smoking	21 (70)	10 (66.7)	11 (73.3)	0.691
ASA score
2	26 (83.8)	14 (87.5)	12 (80)
3	5 (16.2)	2 (12.5)	3 (20)	0.593
Pathology
Adenocarcinoma	15 (48.4)	9 (56.3)	6 (40)
SCC	14 (45.2)	6 (37.5)	8 (53.3)
Benign	2 (6.5)	1 (6.3)	1 (6.7)	0.651
Tumor location
Middle	2 (6.5)	0	2 (13.3)
Distal	21 (67.7)	11 (68.6)	10 (66.7)
GEJ	8 (25.8)	5 (31.3)	3 (20)	0.221
Neoadjuvant therapy
No	12 (38.7)	5 (31.3)	7 (46.7)
Yes	19 (61.3)	11 (68.8)	8 (53.3)	0.371

¹χ².

²T-test.

³Mann-Whitney U test.

ASA: American Society of Anesthesiologists; CAD: Coronary artery disease; DM: Diabetes mellitus; GEJ: Gastroesophageal junction; ModVAC: Modified, endoscopy-independent prophylactic vacuum-assisted closure system; SCC: Squamous cell carcinoma.